Back to List View Graph View

T-cell receptor (TCR)

The T-cell receptor (TCR) is a membrane-bound antigen receptor expressed by T lymphocytes and is central to adaptive immunity.

Where the papers sit

13 papers from the last 6 months study T-cell receptor (TCR) directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 5 human data · 7 preclinical · 1 unclassified

Themes one subject · 1 paradigm shift · 1 new direction

Those 13 are all about one subject.

  • TCR-Based Cancer Immunotherapy

    Cancer-specific TCR discovery is moving toward engineered therapies that recognize peptide-HLA targets despite tumour heterogeneity. TCR-JANUS and other bispecific scaffolds, immunoglobulin constant-domain targeting, and stem-cell-derived off-the-shelf cytotoxic cells broaden therapeutic designs. Structural energetics, machine-learning specificity models, and circVDJ-seq aim to make receptor selection and clonotype tracking more scalable and precise. Antigen-specific T-cell IFNγ, checkpoint blockade, and CAR/TCR combinations remain complementary routes, while aging, sex, CMV, and escape variants identify biological limits that still require resolution.

    13 papers

PARADIGM SHIFT

Antigen heterogeneity need not remain a terminal limitation of antigen-specific TCR therapy

The KRAS-G12V/Trop2 TCR-JANUS engager study and the MART-1-specific TCR-T/RSL3 melanoma heterogeneity study both treated antigenically heterogeneous tumors, but found that antigen-divergent escape could be eliminated by adding a second killing route: TCR-JANUS redirected TCR-T cells to Trop2-positive cells while preserving cognate pHLA recognition, whereas RSL3-induced ferroptosis, enhanced by T-cell-derived IFNγ, eradicated β2-microglobulin-deficient antigen-negative cells. Together, these findings replace the assumption that TCR specificity necessarily confines therapy to cells displaying the original target and establish combination designs that extend activity across heterogeneous tumor populations 42715334Sep 42397036Jul.

NEW DIRECTION

Oncolytic-virus engagement of the endogenous TCR can be used to program CAR-T-cell state and durability rather than to recognize the tumor directly

The vesicular-stomatitis-virus/CAR-T solid-tumor study used the endogenous TCR as an activation and programming input for CAR-T cells, generating antiviral TCR-primed CAR-T clones with enhanced effector functions, altered activation states, greater durability, and improved antitumor activity. This assigns TCR engagement a role outside the set’s predominant uses in antigen-specific tumor recognition, TCR engineering, or repertoire measurement: it becomes a tool for fine-tuning the phenotype of cells whose tumor targeting is provided by a CAR 42247513Jun.

Papers

The 13 papers from the last 6 months that study T-cell receptor (TCR) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

TCR-Based Cancer Immunotherapy (13)
  1. Cancer-specific T cell receptor discovery using 150,000 clinical genomics samples. Science translational medicine · 4 Nov 2026 PMID 42981429
  2. Nonlinear Aging of the Human TCR Repertoire Is Influenced by Sex, CMV, and Cancer. Aging cell · 25 Oct 2026 PMID 42928046
  3. TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. Science advances · 9 Sept 2026 PMID 42715334
  4. Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens. mAbs · 1 Sept 2026 PMID 42680712
  5. Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma. Blood · 24 Aug 2026 PMID 42636156
  6. Deep mapping of structural perturbations to energetics enables precise TCR design. Cell reports methods · 20 Aug 2026 PMID 42624108
  7. Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors. Cell reports. Medicine · 19 Aug 2026 PMID 42617602
  8. Predicting specificity of TCR-pMHC interactions using machine-learning and biophysical models. Cell systems · 13 Aug 2026 PMID 42594866
  9. Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity. Cancer immunology research · 3 Jul 2026 PMID 42397036
  10. Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
  11. circVDJ-seq for T cell clonotype detection in single-cell and spatial multi-omics. Genome medicine · 11 Jun 2026 PMID 42271498
  12. Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity. Science advances · 5 Jun 2026 PMID 42247513
  13. Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells. Molecular therapy : the journal of the American Society of Gene Therapy · 4 Jun 2026 PMID 42237538

By study type

Human data, design not indexed (5)
  1. Cancer-specific T cell receptor discovery using 150,000 clinical genomics samples. Science translational medicine · 4 Nov 2026 PMID 42981429
  2. Nonlinear Aging of the Human TCR Repertoire Is Influenced by Sex, CMV, and Cancer. Aging cell · 25 Oct 2026 PMID 42928046
  3. Deep mapping of structural perturbations to energetics enables precise TCR design. Cell reports methods · 20 Aug 2026 PMID 42624108
  4. Predicting specificity of TCR-pMHC interactions using machine-learning and biophysical models. Cell systems · 13 Aug 2026 PMID 42594866
  5. Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells. Molecular therapy : the journal of the American Society of Gene Therapy · 4 Jun 2026 PMID 42237538
Preclinical: animal, cell and lab studies (7)
  1. TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. Science advances · 9 Sept 2026 PMID 42715334
  2. Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens. mAbs · 1 Sept 2026 PMID 42680712
  3. Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma. Blood · 24 Aug 2026 PMID 42636156
  4. Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors. Cell reports. Medicine · 19 Aug 2026 PMID 42617602
  5. Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity. Cancer immunology research · 3 Jul 2026 PMID 42397036
  6. Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
  7. Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity. Science advances · 5 Jun 2026 PMID 42247513
Unclassified: not yet indexed with MeSH (1)
  1. circVDJ-seq for T cell clonotype detection in single-cell and spatial multi-omics. Genome medicine · 11 Jun 2026 PMID 42271498